US 12,234,295 B2
Chimeric transmembrane protein comprising antibody dimerization domains and a type I cytokine receptor endodomain, encoding nucleic acids thereof and methods of use thereof
Martin Pulé, London (GB); Shaun Cordoba, London (GB); Matteo Righi, London (GB); James Sillibourne, London (GB); Shimobi Onuoha, London (GB); and Simon Thomas, London (GB)
Assigned to AUTOLUS LIMITED, London (GB)
Filed by AUTOLUS LIMITED, London (GB)
Filed on Jul. 26, 2022, as Appl. No. 17/815,110.
Application 16/998,756 is a division of application No. 16/113,224, filed on Aug. 27, 2018, granted, now 10,800,855.
Application 17/815,110 is a continuation of application No. 16/998,756, filed on Aug. 20, 2020, granted, now 11,479,613.
Application 16/113,224 is a continuation of application No. 15/753,486, granted, now 10,800,854, previously published as PCT/GB2016/052564, filed on Aug. 19, 2016.
Claims priority of application No. 1514875 (GB), filed on Aug. 20, 2015.
Prior Publication US 2023/0133682 A1, May 4, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/715 (2006.01); A61K 39/00 (2006.01); C07K 14/46 (2006.01); C07K 16/30 (2006.01); C12N 5/0783 (2010.01)
CPC C07K 16/3069 (2013.01) [A61K 39/001116 (2018.08); A61K 39/001135 (2018.08); A61K 39/001182 (2018.08); A61K 39/001194 (2018.08); A61K 39/4611 (2023.05); A61K 39/4631 (2023.05); A61K 39/464494 (2023.05); A61K 39/464495 (2023.05); C07K 14/46 (2013.01); C07K 14/7155 (2013.01); C12N 5/0636 (2013.01); A61K 2039/55522 (2013.01); C07K 2317/56 (2013.01); C07K 2317/622 (2013.01); C07K 2319/70 (2013.01)] 22 Claims
 
1. A chimeric transmembrane protein comprising:
(i) a first polypeptide which comprises
(a) a first dimerization domain comprising the dimerization portion of an antibody heavy chain constant domain (CH), and
(b) a first chain of a Type I cytokine receptor endodomain; and
(ii) a second polypeptide which comprises
(a) a second dimerization domain comprising the dimerization portion of an antibody light chain constant domain (CL), which dimerizes with the first dimerization domain, and
(b) a second chain of a Type I cytokine receptor endodomain;
wherein the first and second polypeptides spontaneously dimerize.